

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INITIATIVE FOR MEDICINES, ACCESS & KNOWLEDGE (I-MAK), INC.
Petitioner

v.

GILEAD PHARMASSET LLC
Patent Owner

Case IPR2018-00122
Patent 8,334,270

**PATENT OWNER GILEAD PHARMASSET LLC'S
PRELIMINARY RESPONSE**

TABLE OF CONTENTS

I. INTRODUCTION1

II. THE SOFIA '270 PATENT3

 A. Hepatitis C and the previous treatments.....4

 B. Many researchers tried to develop anti-HCV drugs but failed.5

 1. Changes to nucleoside structure can have significant and unpredictable impacts on activity and toxicity.....6

 2. Persons of ordinary skill in this field understood that the effectiveness of prodrugs was unpredictable and nucleoside-specific.....9

 C. Sofosbuvir was a “game-changing” treatment for HCV.....10

 D. The Sofia '270 patent claims11

III. ARGUMENT.....11

 A. I-MAK’s proposed combination of Clark '147 and Clark 2005 is flawed. ...16

 1. I-MAK fails to show that a person of ordinary skill would select the genus of Clark '147 claim 40 as a lead compound for modification.17

 2. I-MAK fails to show that a person of ordinary skill would select the inactive uridine analog instead of the active cytidine analog.....23

 B. I-MAK’s proposed combination of Clark '147 and Clark 2005 with Perrone or McGuigan '327 is flawed.....26

 1. I-MAK fails to show that a person of ordinary skill would modify the nucleoside of Clark '147/Clark 2005 with the phosphoramidate prodrug of Perrone, or have a reasonable expectation of success of doing so.....27

 2. I-MAK fails to show that a person of ordinary skill would modify the nucleoside of Clark '147/Clark 2005 with the isopropyl ester of McGuigan '327, or have a reasonable expectation of success of doing so.30

C. Dr. Fortunak’s opinions are conclusory and insufficient to support
institution35

IV. PRESERVATION OF RIGHTS UNDER *OIL STATES*.....36

V. CONCLUSION.....37

LIST OF EXHIBITS

Exhibit No.	Exhibit Description
GIL 2001	Carroll et al. <i>Nucleoside Analog Inhibitors of Hepatitis C Virus Replication</i> . Infectious Disorders – Drug Targets, 2006
GIL 2002	Chung, M.D. et al. <i>Curing Chronic Hepatitis C – The Arc of a Medical Triumph</i> . The New England Journal of Medicine, 2014.
GIL 2003	Tucker, Miriam E. <i>FDA Approves ‘Game Changer’ Hepatitis C Drug Sofosbuvir</i> . Medscape, 2013.
GIL 2004	HARVONI® label
GIL 2005	Norton, Amy. <i>Hepatitis C Killing More Americans than HIV: Studies</i> . Reuters, 2012.
GIL 2006	Secrist III et al. <i>Clofarabine: From Design to Approval</i> . Modified Nucleosides: in Biochemistry, Biotechnology and Medicine, 2008.
GIL 2007	<i>America’s Overspend: How the Pharmaceutical Patent Problem is Fueling High Drug Prices</i> . I-MAK, 2017.
GIL 2008	I-MAK: Our People
GIL 2009	Lawitz et al. <i>Development of Sofosbuvir for the Treatment of Hepatitis C Virus Infection</i> . Annals of the New York Academy of Sciences, 2014.
GIL 2010	Ninburg, Michael. <i>Hepatitis C Deserves the Attention</i> . Seattlepi.com, 2007.
GIL 2011	Pollack, Andrew. <i>F.D.A. Approves Pill to Treat Hepatitis C</i> . The New York Times, 2013.
GIL 2012	Rockoff, Jonathan D. <i>FDA Approves Gilead’s Hepatitis C Drug</i> . The Wall Street Journal, 2013.
GIL 2013	RESERVED
GIL 2014	RESERVED
GIL 2015	Sofia et al. Discovery of a β -D-2’-Deoxy-2’- β -C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus. Journal of Medicinal Chemistry Article, 2010.
GIL 2016	Thompson et al. <i>Review Article: Investigational Agents for Chronic Hepatitis C</i> . Alimentary Pharmacology & Therapeutics, 2009.
GIL 2017	Meier, C. <i>Pro-Nucleotides – Recent Advances in the Design of</i>

	<i>Efficient Tools for the Delivery of Biologically Active Nucleoside Monophosphates.</i> Synlett, 1997
GIL 2018	Pierra et al. <i>Synthesis and Pharmacokinetics of Valopicitabine (NM283), an Efficient Prodrug of the Potent Anti-HCV Agent 2'-C-Methylcytidine.</i> J. Med. Chem., 2006
GIL 2019	Krise et al. <i>Prodrugs of Phosphates, Phosphonates, and Phosphinates.</i> Advanced Drug Delivery Review, 1996.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.